Ibrutinib as part of risk-stratified treatment for posttransplant lymphoproliferative disorder: the phase 2 TIDaL trial.
Chaganti S, Maycock S, McIlroy G, Jackson A, Bishop R, Johnson S, Kanfer E, Kassam S, Cwynarski K, Wrench D, Arumainathan A, Fox CP, Johnson R, McKay P, Paneesha S, Rowntree C, Balotis C, Collins GP, Davies A, Wright J, Burns S, Laurence A, Wheatley K, Menne T.
Chaganti S, et al. Among authors: maycock s.
Blood. 2024 Jul 25;144(4):392-401. doi: 10.1182/blood.2024023847.
Blood. 2024.
PMID: 38643491
Clinical Trial.